This product is for research use only, not for human use. We do not sell to patients.
| Size | Price | Stock |
|---|---|---|
| 100mg | $1450 | Check With Us |
| 250mg | $2350 | Check With Us |
| 500mg | $3525 | Check With Us |
: Cat #: V4642 CAS #: 646502-53-6 Purity ≥ 98%
Description: VcMMAE (mc-vc-PAB-MMAE), a derivative of MMAE (monomethyl auristatin E) with a valine-citrulline (Vc) linker, is a drug-linker conjugate for ADC (antibody-drug-conjugate) with potent antitumor activity by utilizing the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). VcMMAE is a anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). Monomethyl auristatin E (MMAE) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells. In International Nonproprietary Names for MMAE-MAB-conjugates, the name vedotin refers to MMAE plus its linking structure to the antibody. It is a potent antimitotic drug derived from peptides occurring in marine shell-less mollusc Dolabella auricularia called dolastatins which show potent activity in preclinical studies, both in vitro and in vivo, against a range of lymphomas, leukemia and solid tumors. These drugs show potency of up to 200 times that of vinblastine, another antimitotic drug used for Hodgkin lymphoma as well as other types of cancer
References: [1]. Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 1316.63 |
|---|---|
| Molecular Formula | C68H105N11O15 |
| CAS No. | 646502-53-6 |
| Storage | -20℃ for 3 years in powder formrr |
| -80℃ for 2 years in solvent | |
| SMILES Code | CC[C@@H]([C@H](N(C([C@@H](NC([C@@H](N(C(OCC1=CC=C(NC([C@@H](NC([C@@H](NC(CCCCCN2C(C=CC2=O)=O)=O)C(C)C)=O)CCCNC(N)=O)=O)C=C1)=O)C)C(C)C)=O)C(C)C)=O)C)[C@H](OC)CC(N3CCC[C@H]3[C@H](OC)[C@H](C(N[C@@H]([C@@H](O)C4=CC=CC=C4)C)=O)C)=O)C |
| Synonyms | MMAE antibody conjugate; VcMMAE; MC-VC-PAB-MMAE; Vc-MMAE; MMAE Vc linker; mc-vc-PAB-MMAE; |
| Protocol | In Vitro | Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30+ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells. MMAE sensitized colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells. |
|---|---|---|
| In Vivo | Monomethyl auristatin E (MMAE) in combination with IR results in tumor growth delay, tumor-targeted ACPP-cRGD-MMAE with IR produces a more robust and significantly prolonged tumor regression in xenograft models. |
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 0.7595 mL | 3.7976 mL | 7.5951 mL | 15.1903 mL |
| 5mM | 0.1519 mL | 0.7595 mL | 1.5190 mL | 3.0381 mL |
| 10mM | 0.0760 mL | 0.3798 mL | 0.7595 mL | 1.5190 mL |
| 20mM | 0.0380 mL | 0.1899 mL | 0.3798 mL | 0.7595 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.